Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Change in Account Payables (2023 - 2025)

Historic Change in Account Payables for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to $1.2 million.

  • CG Oncology's Change in Account Payables rose 39566.27% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 9296.03%. This contributed to the annual value of $3.3 million for FY2024, which is 6277.34% up from last year.
  • Latest data reveals that CG Oncology reported Change in Account Payables of $1.2 million as of Q3 2025, which was up 39566.27% from $394000.0 recorded in Q2 2025.
  • In the past 5 years, CG Oncology's Change in Account Payables ranged from a high of $2.4 million in Q4 2024 and a low of -$415000.0 during Q3 2024
  • For the 3-year period, CG Oncology's Change in Account Payables averaged around $647454.5, with its median value being $394000.0 (2025).
  • Within the past 5 years, the most significant YoY rise in CG Oncology's Change in Account Payables was 1584444.44% (2024), while the steepest drop was 44285.71% (2024).
  • CG Oncology's Change in Account Payables (Quarter) stood at $1.4 million in 2023, then skyrocketed by 76.63% to $2.4 million in 2024, then plummeted by 49.73% to $1.2 million in 2025.
  • Its Change in Account Payables stands at $1.2 million for Q3 2025, versus $394000.0 for Q2 2025 and $214000.0 for Q1 2025.